Ferrari Unveils Most Exclusive One-off Supercar Called P80/C

Ferraris’ new supercar is inspired by some of the company’s iconic racecars with improved design and features.

Built for an anonymous customer, Ferrari has released a gorgeous one-off supercar with incredible design- P80/C. The customer has a long family history of Ferrari fanaticism and that is why Ferrari has unhooked a 488 GT3 race car from any limitations. The car has one of the most unique and powerful body kits. P80/C is inspired by Ferrari’s classic models such as Dino 206 S and 330 P3/P4. The project P80/C started in 2015 with immense investment in design and engineering. Each and every part of this car has been meticulously designed so as to get its aerodynamics perfect.

It’s a pure track car with the chassis of 488 GT3 which allows cab-forward emphasis and elongated rear end. It has curving and muscular shaped wings that merge into side air intakes that goes into the engine. It has low hoods flowing with big arches over all four wheels, smooth wraparound windscreen and significant air intakes concluded with the stylish rear end. The wheel arches have received an exaggeration by at least two inches whereas the rear end of the car has standard 488 tapers down. To channel air back to giant main wing, Ferrari has covered back window with an aerodynamic mini-wing design.

This muscular beast is powered with a 3.9-liter twin turbo V8, which produces an output of 661 horsepower. The interior of the car is very much similar to 488 GT3 which is driver-focused with Alcantara bucket seats along with the six-point harness. Ferrari’s GT Race Driver Alessandro Pier Guidi tested this car during the development at Ferrari’s private Fiorano racetrack in Maranello. The company has not released detailed technical features, although they have released a 12-min documentary video for a closer look.

Naloxone Market To Design A Cohesive And Predictive Business Strategy

Naloxone is a medication which is mainly used to reverse opioid overdose such as morphine and heroine. Naloxone is an opioid antagonist and the U.S. Food and Drug Administration (FDA) list it under prescription drugs, however some countries such as Italy and Australia have rescheduled it as an over-the-counter (OTC) medication. Naloxone products are available in various strengths. Currently, the available strengths of naloxone include 0.4 mg/ml, 1mg/ml, 0.4mg/0.4ml, 4mg/0.1ml, and others. Naloxone are administrated from different routes such as intranasal, intramuscular/subcutaneous, and intravenous. Intranasal naloxone products are the latest product in market which can be administrated by anyone (non-medical professional). However, intravenous products are mainly administrated by medical professional who are properly trained.

Frequent launches and approvals of novel naloxone products is expected to fuel the global naloxone market growth

Increasing launches and approval of novel naloxone products by various regulatory bodies is expected to be a major factor aiding in growth of the market over the forecast period. For instance, in January 2017, the U.S. Food and Drug Administration (FDA) approved Adapt Pharma Inc.’s NARCAN Nasal Spray 2 mg formulation for emergency treatment of known or suspected opioid overdose. In 2016, Mylan N.V. launched its naloxone hydrochloride injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. It is therapeutically equivalent to the naloxone hydrochloride injection 0.4 mg/mL, of Hospira Inc. In September 2017, Mundipharma International Limited received approval from European Medicines Agency (EMA) for its product (intranasal naloxone 1.8 mg) to use in emergency reversal of opioid overdose.

The global naloxone market size was valued at US$ 310.2 Mn in 2017, and is expected to witness a CAGR of 11.4% over the forecast period (2018 – 2026).

Request A Sample Copy Of This Report:

https://www.coherentmarketinsights.com/insight/request-sample/1804

Increasing cases of opioid overdose is expected to increase demand for naloxone products during emergency treatments which in turn will positively drive the global naloxone market growth. For instance, according to the data published by the U.S. Department of Health and Human Services (HHS) in 2016, around 11.5 million people misuse prescription drugs and around 948,000 people use heroin. According to the data published by National Institute on Drug Abuse, 2018, in the U.S., everyday over 115 people die due to opioid overdosing. According to same source, in the U.S. opioid overdose increased by 30% from July 2016 through September 2017 in 52 areas in 45 states.Reimbursement scenario for drugs play a major role in adoption of high cost products in developed regions such as North America and Europe. Therefore, favorable reimbursements for naloxone products is expected to support the adoption of these products. Currently, most types of insurance cover and reimburse for naloxone administered directly in a medical setting.

Furthermore, some states in the U.S. have started covering take-home naloxone. Hence, adoption of take-home naloxone is expected to increase in the near future. For instance, in New York State from January 2014, the state’s Medicaid program began to cover the intramuscular formulation of take?home naloxone.

North America naloxone market is expected to a hold dominant position over the forecast period due to the presence of novel naloxone products such as Narcan nasal spray and EVZIO (naloxone hydrochloride injection), which is still not present in any other region. Furthermore, initiatives taken by various companies and organizations to increase access of naloxone is expected to fuel the market growth. For instance, in February 2018, Loyola Medicine and the Cook County Department of Homeland Security and Emergency Management collaborated, where Loyola Medicine trained police officials to use Narcan in case of opioids overdose. In 2016, Adapt Pharma Limited partnered with Smith Medical Partners, LLC for distribution of free Narcan (Naloxone HCl) nasal spray in all high schools in the U.S.

Furthermore, Europe naloxone market is expected to show significant growth in the near future, owing to increasing approvals of novel naloxone products in the region. For instance, in July 2017, Indivior Inc., a subsidiary of Indivior Plc., received marketing authorization (MA) from French Regulatory Agency ANSM for its new Nalscue naloxone hydrochloride nasal spray indicated for emergency treatment of characterized or suspected opioid overdose in France.

Click To Reading More On Naloxone Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

Neurodegenerative Disease Treatment Market to Shows Increasing Demand To Be Observed In The Coming Decade

Neurodegenerative diseases involves progressive loss of function and structure of neurons, which sometimes also includes death of neurons. Major cause of neurodegeneration is deposition of toxic protein substance in the brain, which hinders the function of mitochondria in the brain. Some of the neurodegenerative diseases are caused by genetic mutations due to expansion of CAG trinucleotide and poly Q tract, for instance, Huntington’s disease and spinocerebellar ataxias. Some neurodegenerative diseases are caused due to aggregation of misfolded proteins, for instance Alzheimer’s disease, Huntington disease, and Parkinson’s disease. One of the common factors for cell death in neurodegeneration is intrinsic mitochondrial apoptotic pathway, for instance Amyotrophic lateral sclerosis. Alzheimer’s disease is caused due to aggregation of misfolded protein. Parkinson’s disease affects the central nervous system by abnormal accumulation of protein alpha-synuclein bound to ubiquitin in the damaged cells. Huntington’s disease is a genetic disorder that causes breakdown of nerve cells in the brain.

Neurodegenerative Disease Treatment Market Drivers:-

Major driver for growth of the global neurodegenerative disease treatment market is robust pipeline of drugs. For instance, FlorbetapirF 18 sponsored by Avid Radiopharmaceuticals, a pharmaceutical company focused on improving clinical development of drugs completed phase 2 clinical trials in 2017. This drug is used as biomarkers for neurodegenerative diseases such as Alzheimer’s disease. F 18 T807 sponsored by Washington school of medicine is in phase 2 clinical trials since 2015. This drug is used to treat Amyotrophic Lateral Sclerosis (ALS).

Request A Sample Copy Of This Report:

https://www.coherentmarketinsights.com/insight/request-sample/1860

Mergers and acquisitions by market players are expected to drive the neurodegenerative disease treatment market growth. For instance, in June 2018, Alexion Pharmaceuticals Inc., US-based global biopharmaceutical company merged with Complement Pharma, Netherlands-based biotech company to develop preclinical C-6 complement inhibitor CP010 for neurodegenerative disorders such as Parkinson’s disease and Amyotrophic Lateral Sclerosis (ALS). C6 inhibition prevents the formation of Membrane attack complex (MAC), a complex of terminal complement proteins, which has potential to treat a variety of central nervous system disorders. Launch of new drugs and high prevalence of neurodegenerative diseases are expected to support the growth in neurodegenerative disease treatment market size. For instance, in 2018, ArunA Biomedical launched exosome (Cell derived vesicles that are present in blood) biologic to treat Central Nervous System (CNS) and neurodegenerative diseases. Exosome biologics are used in treatment of CNS and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS).

Increasing research for neurodegenerative diseases treatment is expected to boost growth of neurodegenerative disease treatment market. For instance, E-Scape Bio, a biopharmaceutical company, would be investing more than US$ 63 million on research for treatment of Parkinson’s and Alzheimer’s disease from 2017 for development for new drug. Lack of reimbursement policies provided by the government and hospitals for the treatment of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS) are restraining growth of the market.

Neurodegenerative Disease Treatment Market Regional Analysis:-

North America is expected to hold dominant position in global neurodegenerative disease treatment market due to the strategic mergers and acquisitions among key players. For instance, in 2018, Abbvie Inc. a biopharmaceutical company merged with Voyager Therapeutics, a gene therapy developing company to develop gene therapies to treat Alzheimer’s disease. In 2014, Bristol Myers Squibb, an American pharmaceutical company acquired iPierian Inc. a drug discovery platform that develops therapies for neurodegenerative diseases. Bristol Myers Squibb acquired iPierian’s leading drug IPN007. IPN007 is a monoclonal antibody to treat progressive supranuclear palsy (a medical condition in which consists of deterioration of cells in various areas of brain that control thinking and body movement). Europe neurodegenerative disease treatment market is expected to witness a significant growth due to increasing prevalence of neurodegenerative diseases. According to a survey conducted by Parkinson Association of the Carolinas in 2016, more than 60000 new people in the U.S. are diagnosed with Parkinson’s disease annually. Therefore, increasing number of neurodegenerative disorders is in turn driving growth of the neurodegenerative disease treatment market.

Neurodegenerative Disease Treatment Market Key Players:-

Key players operating in global neurodegenerative disease treatment market include Novartis AG, Pfizer Inc., Merck Serono, Biogen Inc., Teva Pharmaceutical Industries Ltd., UCB, C.H. Boehringer Sohn AG & Ko. KG, Sanofi S.A., GlaxoSmithKline, and Neuro-Hitech Inc.

Click To Reading More On Neurodegenerative Disease Treatment Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

Blood Irradiation Market Report Size |Sales Analysis |Growth Trends

Blood irradiation is a therapy in which blood components are irradiated prior to transfusion, to prevent proliferation of certain types of T lymphocytes. These T lymphocytes inhibit the immune responses and can cause a rare graft-versus-host disease (GVHD) with serious complication due to blood transfusion caused by white blood cells. A small number of white blood cells can recognize the different blood in the body which may cause serious illness or death.

Irradiated blood is treated with UV, X-rays or other forms of radioactive methods. Blood irradiation treated with UV rays is beneficial to cancer patients as it strengthens the immune system and improves overall health. Ultraviolet rays restrain viral, bacterial, and fungal growth and improves the body’s ability to detoxify and inactive toxins, which can further assist in the other cancer treatments. Based on this technique, three types of blood irradiation are available in the market i.e. intravenous laser blood irradiation, transcutaneous laser blood irradiation, and extracorporeal blood irradiation.

Global Blood Irradiation Market Dynamics

Increasing global population vulnerable to various communicable and non-communicable diseases (NCD’s) such as cancer, chronic kidney disease, high blood pressure disease, stroke and cardiovascular diseases, which is expected to drive the global blood irradiation market growth. For instance, according to the World Bank’s 2016 report, the global population reached up to 7.44 billion.

According to a report by World Health Organization (WHO) 2018, non-communicable diseases cause around 41 million deaths each year, which is equivalent to 71% of all deaths globally. Also, cardiovascular diseases account for 17.9 million deaths each year, followed by other respiratory diseases (3.9 million), diabetes (1.6 million), and cancer (9.0 million) respectively. Such increasing prevalence of non- communicable diseases boosts demand for quicker blood stream treatment, which in turn is expected to significantly propel growth of the blood irradiation market. Infections in the blood stream are diagnosed and irradiated by laser irradiation therapies. Increasing use of such therapies is driving manufacturers to develop innovative blood irradiation systems for improved health treatments, which is directly boosting the market growth. For instance, in 2017 thriveMD, a U.S.-based company, introduced ultraviolet blood irradiation (UVB) therapy, which is a photo-oxidation treatment that briefly exposes a sample of the blood to ultraviolet light.

Request A Sample Copy Of This Report:

https://www.coherentmarketinsights.com/insight/request-sample/1939

However, regulatory policies regarding the medical systems and lack of skilled professionals in emerging economies are likely to hamper the market growth. For instance, The Center for Biologics Evaluation and Research (CBER) regulates the collection of blood and blood components used for transfusion, CBER develops and enforces quality standards, inspects blood establishments and monitors reports of errors, accidents and adverse clinical events.

Global Blood Irradiation Market – Regional Insights

Based on the region, the global blood irradiation market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America accounted for the dominant position in the blood irradiation market, owing to growing awareness among the population regarding blood related diseases and launch of new innovative technology in the field of healthcare. For instance, in 2017, Typenex Medical launched Rad-Control, a new irradiation indicator tag technology for blood centers and blood banks in Canada and the U.S. This checks blood irradiation by visual verification, minimizes current documentation practices, and increases efficiency for healthcare staff.

Asia Pacific is expected to show significant growth in the global blood irradiation market followed by Europe. Rising population vulnerable to various chronic diseases and government involvement in maintaining safety standards for new product launches is expected to propel the blood irradiation market growth in the region. For instance, in 2015, UVLrx Therapeutics received CE Marking (European Conformity) for its intravenous UV light therapy device, that offers intravenous, concurrent delivery of ultraviolet-A (UVA), and multiple visible light wavelengths.

Global Blood Irradiation Market – Competitive Landscape

Major players operating in the global blood irradiation market include Typenex Medical, UVLrx Therapeutics, Best Theratronics, Hitachi Medical Systems, Actemium NDT-PES, Rad Source Technologies, and Gilardoni S.p.A. Market players are engaged in adopting strategies such as mergers, collaborations, new product launches, and partnerships to retain their position in the market. For instance, in 2017 Typenex Medical exclusively partnered with a European manufacturer- On Point Indicators GmbH, to offer its product to customers.

Click To Reading More On Blood Irradiation Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cancer

Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.

These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch of new ready to eat products are expected to fuel growth of the oncology nutrition market.

Collaborations of key players to increase awareness for nutrition of cancer patients is also expected to drive growth of the oncology nutrition market. For instance, in 2017, Celgene Corporation, a U.S based biotechnology company, collaborated with Savor Health, which offers cancer patients expert dietary solutions.

Get The Holistic SAMPLE With Research Methodology:

https://www.coherentmarketinsights.com/insight/request-sample/1954

Celgene Corporation collaborated with Savor Health to be a part of their awareness program ‘Cooking. Comfort. Care’ to increase awareness of importance of nutritional food for pancreatic cancer patients. Such campaigns that create awareness about nutritional food for cancer patients are expected to significantly contribute to growth of the oncology nutrition market.

According to a study conducted by National Cancer Institute in 2018, around 15,112,098 people in U.S. were diagnosed with cancer in 2015, whereas in 2018 around 17 million new cases of cancer were recorded. High prevalence of cancer is expected to boost the oncology nutrition market growth.

However, high cost of oncology nutrition products is expected to restrain the oncology nutrition market growth. For instance, Nutricomp Energy HP by B. Braun Melsungen AG costs more than US$ 8898 which most people cannot afford. Thus high cost of nutritional products for cancer patients is expected to restrain the growth of oncology nutrition market.

Click To Continue Reading On Oncology Nutrition Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

H1N1 Vaccines Market Future Need Highlights 2026

H1N1 influenza virus causes viral disease, commonly known as swine flu, which mostly affects the respiratory system. Swine flu is characterized by infection from H1N1 strain. Symptoms of H1N1 flu are fever, cough, sore throat, runny or stuffy nose, watery and red eyes, body aches, headache, fatigue, and diarrhea. H1N1 spreads through contact with contaminated air or geographical locations infected with virus. H1N1 infection may worsen other chronic respiratory conditions such as bronchitis, pneumonia, COPD, and sometimes even death due to respiratory failure. H1N1 vaccine is an important innovation to tackle the H1N1 pandemic since 2009. Initially, the vaccines developed or available were inactivated monovalent vaccines that could prevent infection from most of the strains of H1N1. There are two routes of administration such as intradermal for inactivated vaccine and intranasal for live attenuated vaccine. Both routes shown efficacy profile and are bioequivalent against preventing H1N1 infection. Global H1N1 vaccine market has presence of both multinational pharmaceutical companies and companies from emerging economies.

H1N1 Vaccines Market – Market Dynamics

One of the major factor propelling growth of H1N1 market is increased incidence of disease and episodes of pandemic worldwide from H1N1 infection. According to World Health Organization’s (WHO) 2018, factsheet estimates, 290,000 to 650,000 deaths are reported each year from all types of influenza infection (including Influenza A i.e. H1N1). Each year there are 3 to 5 million cases of severe illness from viral influenza infection globally, according to the same source.

Government initiatives, both internationally and nationally, to tackle H1N1 pandemic would positively impact the market growth. Health institution such as World Health Organization (WHO) have been instrumental in developing vaccines and supporting efficient distribution of the vaccine. After 2009 pandemic of H1N1 influenza, the U.S. government initiated US$ 3 billion H1N1 vaccine project under which it contracted five major companies to develop vaccine for H1N1 influenza. Under the WHO’s Global Influenza Surveillance and Response System, National Influenza Centers and WHO Collaborating Centers are continuously monitoring the influenza viruses circulating in humans and updates the composition of influenza vaccines twice a year.

Furthermore, rising geriatric population worldwide would be another impetus for growth of the H1N1 vaccine market. Global population is crossing the age of 60 at annual rate of 3% according to 2017 UN report. Increased age, maximizes the risk of various respiratory tract related diseases and immune deficient diseases, thereby the risk for infection due to H1N1 virus rises. Awareness amongst patients about preventive healthcare approaches such as vaccination may lead to higher demand for H1N1 vaccines during forecast period.

Request A Sample Copy Of This Report:

https://www.coherentmarketinsights.com/insight/request-sample/2056

However, seasonal nature of occurrence of H1N1 flu has led to meagre revenue for many of the key players. For instance, India-based Serum Institute, which produces intranasal live vaccine to treat swine flu had to destroy stock of 2 million doses in the year 2011 due to lack of demand. In contrast, if pandemic arises suddenly, supply of vaccine may be delayed due to slow production of vaccine, which may negatively affect health of many patients. Due to constant evolving nature of H1N1 virus, vaccine may prove to be ineffective in some parts of the world, which may deter the use of vaccines.

H1N1 Vaccines Market – Regional Insights

On the basis of geography, H1N1 vaccines market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to lead the H1N1 vaccines market during the forecast period. This is due to increasing government initiatives for prevention of H1N1 infection. U.S. which faced major epidemic in 2009. After this pandemic the U.S. has strengthen the preventive approach to control H1N1 outbreak by implementing vaccination program. According to statistics given by Centre for Disease Control  and Prevention in February 2018, during October 1, 2017 and  February 3, 2018, clinical laboratories tested 666,493 specimens for influenza virus, 124,316 (18.7%) of which tested positive for influenza virus. 84.3% of these tested positive for influenza A.

Furthermore Asia Pacific market is expected to exhibit the highest CAGR due to high prevalence of swine flu and increasing awareness about vaccination against H1N1. According to Ministry of Health and Family Welfare, Government of India, there were 0.1 million cases in India of H1N1 influenza during 2010 to 2017. Continuous changing nature of the virus creates challenges to overcome the H1N1 epidemic. For instance, in 2017 new Michigan strain of H1N1 swine flu virus was first identified in India. Government has played an important role in tackling swine flu by spreading awareness about H1N1 vaccine The Government of India has published guidelines for case management of influenza A/H1N1 which classifies influenza patients into three categories depending on severity. Vaccination was recommended in patient group which are susceptible to H1N1 fever in future.

H1N1 Vaccines Market – Competitive Landscape

Key players present in the H1N1 vaccines market are Medimmune, AstraZeneca, GlaxoSmithKline, Novartis, Serum Institute of India, Abbott Healthcare, Sanofi Pasture, CSL Biotherapeutics, Sinovac, ID Biomedical Corporation, Cadila Healthcare, and Lupin Ltd.

Click To Reading More On H1N1 Vaccines Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

Peyronie’s Disease Treatment Market Predicted to Witness a Thriving Growth by 2026

Peyronie’s disease (PD) is condition wherein the penis is curved or bent due to development of plaque or a fibrous scar tissue inside the penis. This condition can cause painful erections and the penis gets bent while it is erected. The bent is towards the side where plaque is being formed i.e. either downwards or upwards. The condition is identified by a major bend or pain. In a few people Peyronie’s disease may go away on its own. However, in most cases it may remain stable or worsen. Hence, it is advisable to visit an urologist to avoid consequences in future. Treatment may be needed if the curvature prevents successful sexual intercourse.

Peyronie’s disease is a rare condition observed in about 6 out of 100 men in the age group of 40 to 70 years. Moreover, the Urology Care Foundation also estimates that the number of people affected by this condition can be higher than this as many men are embarrassed and do not see their healthcare provider. It is mostly at times when the men visit the healthcare practitioner for erectile dysfunction treatment and the healthcare practitioner may notice Peyronie’s disease. Lack of awareness among patients has resulted in under reporting of this condition.

Peyronie’s Disease Treatment Options

The exact cause of plaque formation is not known. Hence, treatment is done with the available research and knowledge of plaque formation. There are various treatment options followed for Peyronie’ disease basis on which the market is analyzed. These include drugs, surgery and devices. The drugs market can be analyzed based on the administration route i.e. oral and injectable. Drugs prescribe through oral route include Vitamin E, Potassium amino-benzoate (“Potaba”), Tamoxifen, Colchicine, and Carnitine. Similarly, the injectable drugs include Verapamil, Interferon, and Collagenase. Use of oral drugs is limited as none of the studies conducted so far for Peyroniee’s disease have shown positive results of these drugs over the placebo.

Request A Sample Copy:

https://www.coherentmarketinsights.com/insight/request-sample/61

On the other hand injectables show some positive outcomes over placebo. However, more studies are required to establish the efficacy. Studies with collagenase have shown positive outcomes for its use in Peyronie’s disease. Therefore, Xiaflex (Collagenase clostridium histolyticum) from BioSpecifics Technologies Corporation is the only FDA approved product indicated for Peyronie’s disease in adult men. Approved in 2013, Xiaflex is marketed in the U.S. by Endo International plc. In Europe, Collagenase clostridium histolyticum is available by the brand name Xiapex.

A penile prosthetic device is another good treatment option for Peyronie’s disease and moderate-to-severe ED. This device helps straighten the penis. Surgical procedure on the other hand involves grafting the space being emptied on removal of the plaque.

With Xiaflex the only FDA approved product for this disease, Endo dominates the market

The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product is estimated to generate USD 100 million in revenue for Peyronie’s disease by 2018. In Japan, BioSpecifics Technologies Corp. has granted Asahi Kasei Pharma the rights to develop and market XIAFLEX in Japan for Peyronie’s disease. Further, the company is also partnering with global companies in Canada, Europe, Mexico, and Brazil for commercializing XIAFLEX for PD.

With increasing awareness and research on this disease, new drug molecules could be made available in the market.

Click To Reading More On Peyronie’s Disease Treatment Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Practice Management System Market Poised to Garner Maximum Revenues During 2018-2026

Practice management system (PMS) helps manage the daily operations of an organization. These systems find wide application across various verticals in an industry. Increasing investments to upgrade healthcare facilities, especially in developed regions and growth of the healthcare IT industry in developing regions, is creating a highly conducive environment for growth of the practice management systems market. Increasing adoption of PMS has been witnessed in emerging nations such as Indian, China, South Africa, and Brazil, in order to streamline operations and in turn provide better healthcare facilities in these countries. PMS allows for efficient management of health data, patient scheduling, billing process, and referral policies.

Physicians and group organizations need to maintain large amounts of data of day-to-day activities. Practice management system addresses these needs, maintaining critical patient information such as patient demographics, appointment schedule, insurance payer data, billing, and diagnostic and treatment history. Practice management system software are often synchronized with electronic medical record (EMR) or electronic health records (EMR) software for better hospital management.

Get The Holistic SAMPLE With Research Methodology:

https://www.coherentmarketinsights.com/insight/request-sample/68

Increasing hospital visiting on the back of rising prevalence of Chronic and Infectious Diseases creating favorable environment for market growth

World Health Organization (WHO) estimates that there would be around 24 million cancer cases globally by 2035. In the U.S., over one-third of the adult population is obese, as revealed by statistics released by Centers for Disease Control and Prevention (CDC) (2016). As obesity is a major predisposing factor to various diseases such as diabetes and other cardiovascular diseases, steep rise in patient population is expected in the near future.

Prevalence of infectious diseases is also on the rise. Moreover, increasing instanced of drug-resistance has mandated physicians to maintain medication history of patient.

Rapid rise in geriatric population: According to WHO, over 2 billion individuals worldwide will be aged 60 years and above by 2050. A detailed report published by CDC projects that by 2030, 20% of the U.S. population would comprise of geriatric people. The report also details that cardiovascular diseases is the leading cause of deaths in adults aged 65 and above in the U.S.

Rapid rise in patients visiting hospitals mandates efficient keeping of patient history and record maintenance, in turn fueling growth of the practice management systems market.

High Installation Cost Hindering Growth in Emerging Economies

The practice management systems market share is mainly concentrated in the U.S. mainly due to presence of dense network of hospitals and existing complex healthcare service management and insurance systems. The healthcare system in the U.S., is very unlike that in other countries. Health Maintenance Organizations (HMOs) and Preferred Provider Organizations (PPOs) have been set up, and thus patients tend to visit multiple physicians. Hence, maintenance of consistence treatment history becomes difficult. The market is also growing in major European countries such as the U.K., France, Germany, Italy, and Spain. The PMS market is yet in its introductory phase in Asia Pacific, Latin America, Africa, and Middle East regions, owing to low diagnosis and treatment rate combined with financial challenges linked with deployment of expensive software systems.

Key Suppliers in the global practice management systems market: Allscripts Healthcare Solutions, Inc. Henry Schein MicroMD, Athenahealth, Inc., GE Healthcare, NextGen Healthcare Information System LLC, Practice Fusion, McKesson Corporation, Greenway Medical AdvantEgde Healthcare Solutions, MediTouch, and Accumedic Computer Systems.

Get Table Of Content:

https://www.coherentmarketinsights.com/ongoing-insight/toc/68

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

Retractable Needle Safety Syringes Market Poised to Garner Maximum Revenues During 2018-2026

A retractable needle safety syringe is a type of safety syringe that comes along with integrated safety mechanism. It is designed in such a way that protruding needle is withdrawn into the barrel of syringe after the delivery of medication/dose. After medication is expelled, the user has to apply extra pressure to the attached plunger to break the seal and to retract the needle into the syringe. The retractable needles are safe and real-time. These syringes also decrease the waste volume as compared to other syringes. Retractable needles syringes are used in several indications such as diabetes, tuberculosis, and cancer.

Major factors driving the growth of global retractable needle safety syringes market are increasing incidences of chronic diseases, rising geriatric population, and growing awareness among the healthcare professionals. According to the American Diabetes Association, in 2015, around 30.3 Americans had diabetes, which is 9.4% of the total U.S population. Moreover, according to the World Health Organization (WHO), in 2015, approximately 8.8 million people suffered from cancer worldwide. Approximately, 70% of the cancer deaths are recorded in low and middle income economies.

According to the World Health Organization (WHO), approximately 16 billion injections are used annually out of which almost 90% are given in curative conditions. The unsafe usage of syringe is observed worldwide especially in emerging economies, which leads to widespread infection amongst healthcare professionals and patients. Unsafe syringe usage can cause hemorrhagic fevers such as Marburg and Ebola viruses, malaria, and others.  According to the statistics published by WHO, 2012, unsafe syringe usage leads to 1.3 million early deaths annually, direct medical costs of US$ 535 million and cumulative loss of 26 million years of life.

Request For Sample Copy:

https://www.coherentmarketinsights.com/insight/request-sample/1189

Global Retractable Needle Safety Syringes Market Taxonomy:

On the basis of product type, the global retractable needle safety syringe market is segmented into:

  • Manual

  • Automated

On the basis of end user, the global retractable needle safety syringe market is segmented into:

  • Hospitals

  • Clinics

  • Ambulatory Surgical Units

Regional segmentation of global retractable needle safety syringe by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, Africa, and Middle East.  For instance, in May 2017, Innovative Neurons LLC, a medical device company announced to commercialize its patented auto retractable multi-needle syringe also known as FAST (fast, accessible, safe and technology). The FAST technology is expected to decrease the 40,000 needle stick injuries, endangering healthcare professional lives, in the U.S per year. It also reduces the time required to inject medication with multiple injections. It is also expected to reduce the cost by 29%, according to the company claims.

Moreover, in December 2017, an Australia-based company, Numedico Technologies signed an agreement with Mana Medical Services. According to agreement, the latter will distribute ClickZip Needle Retractable Safety Syringe in New Zealand and Australia. The ClickZip is conventional syringe with additional locking mechanism.

The market is oligopolistic in nature with few market players dominating the market. The prominent players in the global retractable needle safety syringes market include Retractable Technologies, Inc., Becton, Dickinson and Company, Medtronic plc, Axel Bio Corporation, DMC Medical Limited, Sol-Millennium, Medigard Limited, Smiths Medical Inc., Globe Medical Tech, Inc., and UltiMed, Inc.

Click To Reading More On Retractable Needle Safety Syringes Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

Dry Eye Syndrome Treatment Market Scrutinized in New Research

Dry eye syndrome (DES) is also known as keratisis sicca and keratoconjunctivitis sicca. Patients suffering from DES show damage to the ocular surface, instability in the tear film, and visual disturbance. Tear film covers the ocular surface, which is made up of three intertwined layers, a superficial lipid layer, produced by meibomian glands assist in reducing tear evaporation and uniform tear spreading, middle thick aqueous layer produced from lacrimal glands, and the innermost hydrophilic mucin layer produced from goblet cells of conjunctiva and epithelium of ocular surface.

The two most common types of DES are DES associated with Sjogren syndrome (SS) and DES unassociated with SS. DES can also be classified as aqueous deficiency dry eye and evaporative dry eye disorder. Patients with aqueous tear deficiency (ATD) often suffer from SS if they have shown symptoms of connective tissue disease (CTD) or xerostomia in past. Patients with primary SS showed evidence of autoimmune disease with high presence of ocular surface disease, ATD and serum autoantibodies. According to TearScience Inc., in 2012, around 86% of the patients in Europe and the U.S. were suffering from DES showed symptoms of Meibomian Gland Dysfunction (MGD, blockage of meibomian glands). The blockage causes less secretion of oil in the tears, which results in evaporation of tears too quickly.

The most common symptoms associated with DES are ocular irritation, photophobia, blurry vision, mucoid discharge, ocular dryness, itching, and excessive tearing. DES is diagnosed through tests such as the Schirmer test, tear film osmolarity, tear meniscus height, tear ferning test, measurement of tear break up time, and staining of corneal and conjuctivital epithelium with lissamine green and fluorescein or rose bengal. Topical anti-inflammatory agents (cyclosporine and corticosteroids), omega 3 fatty acids, immunosuppressant, umbilical cord serum, artificial tear substitutes and gels, emulsions, and ointments are the common agents used for treatment of DES. Advanced options for the treatment of DES include conjunctival flap, mucous membrane grafting, lateral tarsorrhaphy, salivary gland duct transposition, amniotic membrane contact lens therapy, and prosthetic replacement of the ocular surface ecosystem (PROSE) lens therapy.

Get The Holistic SAMPLE With Research Methodology:

https://www.coherentmarketinsights.com/insight/request-sample/1173

The global dry eye syndrome treatment market is primarily driven by growing geriatric population coupled with high prevalence of dry eye syndrome and growth in awareness about the diagnosis and treatment of the disease. However, the stringent drug approvals, expirations of the blockbuster drugs patents, and lack of skilled ophthalmologists are restraining the growth of DES market. According to National Health and Wellness Survey in 2013, approximately 16.4 million people are suffering from DES, which accounts for 6.8% of the total population of the U.S. Prevalence of DES increases with age, 2.7% for 18 – 34 age group and 18.6% for more than 75 age group were reported to be suffering from DES. The prevalence of DES is higher in women (8.8%) as compared to men (4.5%). According to the National Eye Institute, in the U.S the annual cost of treating DES including prescription drugs is US $3.84 billion.

High healthcare expenditure and increasing R&D activities in the DES treatment market is expected to propel growth of DES market in North America

Growing geriatric population coupled with high prevalence of dry eye syndrome owing to lifestyle disorders are contributing factors for the growth of DES market in the North America region.

Asia Pacific region is emerging in DES treatment market due to large pool of patient population. According to the regional population based study published in All India Ophthalmological Society, in 2012, the prevalence of DES was 40.8% with mild symptoms and 31.7% with MGD.

Global dry eye syndrome treatment market is oligopolistic in nature with few players holding majority of the share. Various strategies are adopted by market players such as new product launches, acquisitions, and agreements in order to retain market position. In September, 2017, Johnson and Johnson Vision, acquired TearScience Inc., a medical device manufacturer for treating MGD. This acquisition expanded the company’s eye health portfolio. In April 2017, Allergan received marketing approval from FDA for its TrueTear Intranasal Tear Neurostimulator.

Some of the major players operating in the global dry eye syndrome treatment market are Allergan, Novartis AG., Otsuka Pharmaceutical Co. Ltd., Valent Pharmaceuticals, Johnson and Johnson Vision, Acadia Pharmaceuticals, Allostera Pharma, I-Med Pharma Inc., Santen Pharmaceuticals Co. Ltd., AFT pharmaceuticals, Novaliq GmBh, and Auven therapeutics.

Get Table Of Content:

https://www.coherentmarketinsights.com/ongoing-insight/toc/1173

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]